Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00820339 | Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy(SHVE) | completed | Phase 2 / Phase 3 | 132 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00826384 | Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion | completed | Phase 1 / Phase 2 | 352 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 |
| Apr 1, 2016 |
| clinicaltrials |
| NCT00827554 | The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | completed | Phase 2 / Phase 3 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00849264 | Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients | completed | Phase 2 | 120 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT01692704 | Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy | completed | Phase 1 / Phase 2 | 12 | University of ZurichOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT00877071 | LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed(HCC) | completed | Phase 2 | 2 | University of PittsburghOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT00987935 | A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients | completed | Phase 2 | 134 | Boehringer IngelheimINDUSTRY | 2 | Mar 10, 2016 | clinicaltrials |
| NCT01658943 | Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy(S1115) | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2016 | clinicaltrials |
| NCT00055692 | Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00712790 | Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 35 | Singapore Clinical Research InstituteOTHER | 4 | Jan 6, 2016 | clinicaltrials |
| NCT01232296 | A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 4, 2015 | clinicaltrials |
| NCT00807300 | Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma(CEAL) | completed | Phase 2 | 77 | University of MagdeburgOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT02008929 | to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)(MG4101) | completed | Phase 2 | 5 | Samsung Medical CenterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00524498 | A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma | completed | Phase 2 | 60 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 15, 2015 | clinicaltrials |
| NCT01454180 | Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets | completed | Phase 2 | 31 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Oct 9, 2015 | clinicaltrials |
| NCT01073839 | Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma. | completed | Phase 1 / Phase 2 | 33 | University of ZurichOTHER | 1 | Sep 18, 2015 | clinicaltrials |
| NCT00365391 | Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2015 | clinicaltrials |
| NCT01093222 | Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT01406574 | Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 23 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01389414 | Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma(Vecti-BIL) | completed | Phase 2 | 89 | Prof. Massimo AgliettaOTHER | 1 | May 28, 2015 | clinicaltrials |
| NCT00493883 | Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors | completed | Phase 1 / Phase 2 | 81 | Southwestern Regional Medical CenterOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00474812 | Dasatinib in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00107536 | Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00006016 | Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00998322 | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 34 | Oncolytics BiotechINDUSTRY | 1 | Apr 10, 2015 | clinicaltrials |
| NCT00300950 | Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer | completed | Phase 2 | 176 | GlobeImmuneINDUSTRY | 2 | Apr 6, 2015 | clinicaltrials |
| NCT01003015 | Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 36 | BayerINDUSTRY | 4 | Apr 3, 2015 | clinicaltrials |
| NCT00056992 | Testing of ADI-PEG in Hepatocellular Carcinoma | completed | Phase 2 | 34 | FDA Office of Orphan Products DevelopmentFED | 1 | Mar 25, 2015 | clinicaltrials |
| NCT02351219 | FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer(FLAP) | completed | Phase 2 | 50 | Azienda Ospedaliero, Universitaria PisanaOTHER | 1 | Jan 30, 2015 | clinicaltrials |
| NCT01232829 | Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2014 | clinicaltrials |
| NCT00131911 | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2014 | clinicaltrials |
| NCT00108953 | A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 96 | BayerINDUSTRY | 6 | Oct 31, 2014 | clinicaltrials |
| NCT00083226 | Doxorubicin and Bortezomib in Treating Patients With Liver Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00627042 | Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy | completed | Phase 2 | 42 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 8, 2014 | clinicaltrials |
| NCT02202564 | Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 2 | 81 | Huazhong University of Science and TechnologyOTHER | 0 | Jul 29, 2014 | clinicaltrials |
| NCT00577889 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 25, 2014 | clinicaltrials |
| NCT00484211 | Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 40 | AGC Biologics S.p.A.INDUSTRY | 1 | May 30, 2014 | clinicaltrials |
| NCT00331682 | Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00604721 | Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00639509 | IMC-A12 in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00504192 | A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | completed | Phase 2 | 40 | Soonchunhyang University HospitalOTHER | 1 | May 20, 2014 | clinicaltrials |
| NCT00091026 | Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 143 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01082809 | Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma | completed | Phase 2 | 59 | Samsung Medical CenterOTHER | 1 | May 14, 2014 | clinicaltrials |
| NCT01124786 | A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) | completed | Phase 2 | 367 | Clovis Oncology, Inc.INDUSTRY | 15 | Apr 17, 2014 | clinicaltrials |
| NCT00044512 | A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma | completed | Phase 2 | 137 | BayerINDUSTRY | 5 | Apr 16, 2014 | clinicaltrials |
| NCT00203892 | Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma | completed | Phase 1 / Phase 2 | 23 | University of ChicagoOTHER | 1 | Apr 16, 2014 | clinicaltrials |
| NCT00142428 | Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT00142467 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma | completed | Phase 2 | 33 | Massachusetts General HospitalOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT00361309 | SU011248 in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Mar 18, 2014 | clinicaltrials |
| NCT01116635 | Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 24 | University of British ColumbiaOTHER | 1 | Mar 17, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Apr 1, 2016source: clinicaltrials